Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study | Zendy

Federico Longo | Zendy; Mónica Jorge | Zendy; Ricardo Yayá | Zendy; Ana Fernández Montés | Zendy; Nieves Martínez Lago | Zendy; Elena Brozos | Zendy; Jorge Aparicio | Zendy; Guillermo Quintero | Zendy; Eduardo Cervera Ceballos | Zendy; Elvira Buxó | Zendy; Ana Mariá López | Zendy; Meredith Pellon | Zendy; Raquel Molina | Zendy; Laura Díaz-Paniagua | Zendy; Paula Cerdá | Zendy; Pedro López Leiva | Zendy; Alfonso Martín Carnicero | Zendy; A. Cousillas Castiñeiras | Zendy; Lorena Paris | Zendy; Beatriz García-Paredes | Zendy; C. Romero | Zendy; María Eugenia Ortega | Zendy; Alberto Molero | Zendy; Sergio De La Torre | Zendy; MinHua Jen | Zendy; Silvia DíazCerezo | Zendy

AI Assistant Blog Pricing

Open Access

Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study

Author(s) -

Federico Longo,

Mónica Jorge,

Ricardo Yayá,

Ana Fernández Montés,

Nieves Martínez Lago,

Elena Brozos,

Jorge Aparicio,

Guillermo Quintero,

Eduardo Cervera Ceballos,

Elvira Buxó,

Ana Mariá López,

Meredith Pellon,

Raquel Molina,

Laura Díaz-Paniagua,

Paula Cerdá,

Pedro López Leiva,

Alfonso Martín Carnicero,

A. Cousillas Castiñeiras,

Lorena Paris,

Beatriz García-Paredes,

C. Romero,

María Eugenia Ortega,

Alberto Molero,

Sergio De La Torre,

MinHua Jen,

Silvia DíazCerezo

Publication year - 2021

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2020-1216

Subject(s) - ramucirumab , medicine , regimen , cancer , paclitaxel , retrospective cohort study , randomized controlled trial , gastroenterology , oncology

Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, retrospective study carried out in 20 Spanish hospitals, in patients who started ramucirumab treatment between December 2015 and December 2018. Descriptive analysis was conducted for patient characteristics, treatment patterns and effectiveness outcomes. Results: Three hundred seventeen patients were included (93.7% treated with ramucirumab-paclitaxel and 6.3% with ramucirumab); age 62.5 (11.3) years; 66.9% male. Median progression-free survival and overall survival were 3.9 months (95% CI: 3.4–4.3) and 7.4 (95% CI: 6.4–8.9) in combination regimen and 2.0 (1.1–2.8) and 4.3 (95% CI: 1.9–7.3) in monotherapy, respectively. Conclusion: The study findings were consistent with available real-world studies and randomized clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog